Managing Pediatric Neurogenic Detrusor Overactivity (NDO) remains a significant challenge for clinicians, particularly when the condition arises from primary tethered cord syndrome (TCS). These patients often struggle with elevated bladder pressure, which poses a serious risk to the upper urinary tract and renal function. A recent study by Liu D et al. investigated whether combining pharmacological therapy with behavioral interventions could optimize clinical outcomes for these young patients.

Researchers conducted a retrospective analysis of 32 children diagnosed with NDO due to primary TCS. The participants were divided into two equal groups: group A received solifenacin monotherapy, while group B underwent a combined regimen of solifenacin and biofeedback. The clinical team assessed lower urinary tract symptoms, urodynamic parameters, and post-void residual urine (PVRU) at 4, 12, and 24 weeks to track progress.

Addressing Pediatric Neurogenic Detrusor Overactivity with Combined Therapy

The results at the 4-week and 12-week intervals showed that both groups experienced noticeable improvements in urinary symptoms compared to their baseline measurements. However, no statistically significant difference existed between the two treatment arms during these early assessments. This suggests that while solifenacin is effective as an initial intervention, the added benefits of biofeedback take longer to manifest in a measurable way.

By the 24-week mark, a clear distinction emerged between the two cohorts. Group B, which received both solifenacin and biofeedback, exhibited significantly greater improvements in both lower urinary tract symptoms and urodynamic parameters than group A. Consequently, the researchers concluded that the synergy between muscle-relaxing medication and behavioral training offers a more robust long-term solution for bladder dysfunction.

Furthermore, solifenacin works by blocking muscarinic receptors to reduce involuntary detrusor contractions. Biofeedback complements this by teaching the child to coordinate pelvic floor muscles effectively. Therefore, this dual approach addresses both the neurogenic and behavioral components of the condition, leading to more stable bladder compliance and reduced pressure over time.

Frequently Asked Questions

How does biofeedback assist in treating neurogenic detrusor overactivity?

Biofeedback is a non-invasive behavioral therapy that uses electronic monitoring to provide real-time information about pelvic floor muscle activity. It helps children learn how to relax or contract specific muscles, which enhances the effectiveness of medication in controlling bladder pressure.

Is solifenacin safe for long-term use in children with TCS?

Solifenacin is generally well-tolerated in pediatric populations. Common side effects include dry mouth and constipation, which are usually mild. Long-term studies indicate that it effectively manages overactive detrusor contractions without significantly impacting voiding efficiency in most cases.

When should clinicians consider combined therapy instead of monotherapy?

Combined therapy should be considered for children who do not achieve full symptomatic relief with medication alone or for those with high-risk urodynamic profiles. As the study shows, the benefits of combined therapy become more evident after six months of consistent treatment.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Refer to the latest local and national guidelines for clinical practice.

References

1. Liu D et al. Efficacy of Solifenacin Combined with Biofeedback in Children with Neurogenic Detrusor Overactivity Caused by Primary Tethered Cord Syndrome. J Child Neurol. 2026 Mar 17. doi: 10.1177/08830738261425433. PMID: 41841338.

2. Hu and Zhang. Efficacy and safety of solifenacin combined with biofeedback in children with overactive bladder. BMC Urology. 2024;24:97.

3. Newgreen D, et al. Long-term safety and efficacy of solifenacin in children and adolescents with overactive bladder. J Urol. 2017;198(4):928-936.